Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability
- 21 July 2012
- journal article
- research article
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 20 (2) , 223-233
Abstract
Background: The discovery of practical biomarkers is important to realize personalized medicine for patients with malignant neoplasias, including colorectal cancer (CRC).Purpose: The aim of this study was to determine reliable prognostic biomarkers by the analysis of patients with resectable colorectal liver metastases (CRLM).Methods: Genomic DNA was obtained from the CRLM tissues of a cohort of 126 patients with CRLM with curative hepatic resection. The KRAS/BRAF mutation spectrum and microsatellite instability (MSI) status were successfully analyzed in 100 of the 126 CRLM tissues and these findings were examined in relation to the patients' clinical outcomes.Results: The cohort of 100 CRLM patients consisted of 46 with synchronous and 54 with metachronous liver metastasis. Overall survival and disease‐free survival at 5 years were 57.4 and 24.9 %, respectively. MSI analysis revealed that none of the 100 CRLM specimens showed any evidence of MSI. By KRAS/BRAF mutation analysis, the analyzed CRLM patients were divided into 3 groups;KRAS‐mutant (KRAS‐Mt;n = 27), BRAF‐mutant (BRAF‐Mt;n = 3), and wild‐types of both genes (Wild‐type;n = 70). In the survival analysis, both KRAS‐Mt and BRAF‐Mt patients showed significantly poorer prognoses compared with Wild‐type patients. Furthermore, although the population with the BRAF mutation was small, this mutation had a significant negative impact on disease‐free survival.Conclusions: In this study, all tumors in the cohort of CRLM patients were non‐MSI tumors, suggesting MSI cancer in primary CRC would rarely reveal metastatic potential. KRAS and BRAF mutations are suggested to be poor prognostic factors in CRLM. Genetic information has an essential role as a prognostic marker and could contribute to the decisions on treatment strategy for CRLM.Keywords
This publication has 42 references indexed in Scilit:
- BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancerBritish Journal of Cancer, 2011
- KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803Clinical Cancer Research, 2009
- Deficient mismatch repair system in patients with sporadic advanced colorectal cancerBritish Journal of Cancer, 2009
- Prognostic Significance of Defective Mismatch Repair and BRAF V600E in Patients with Colon CancerClinical Cancer Research, 2008
- Mutations in Both KRAS and BRAF May Contribute to the Methylator Phenotype in Colon CancerGastroenterology, 2008
- Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trialThe Lancet, 2008
- RAF/RAS oncogenes and mismatch-repair statusNature, 2002
- Mutations of the BRAF gene in human cancerNature, 2002
- Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ studyBritish Journal of Cancer, 2001